{"entity":{"id":"nct04140526","kind":"trial","name":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","aka":[],"tldr":"A phase 1/2 trial of Gotistobart, Pembrolizumab, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by OncoC4, Inc., active and no longer recruiting.","summary":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC is a phase 1/2 interventional study registered as NCT04140526 by OncoC4, Inc., with 733 participants planned, started 2020-09-16 and due to reach its primary completion in 2026-12-31. Interventions recorded: ONC-392, Pembrolizumab, Docetaxel. Conditions listed: Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04140526","url":"https://clinicaltrials.gov/study/NCT04140526"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","melanoma","rcc","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["gotistobart","pembrolizumab","docetaxel"],"companies":["oncoc4"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04140526","phase":"1/2","setting":"Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)","sponsor":"OncoC4, Inc.","enrolled":733,"outcomes":[]},"route":"/trials/nct04140526/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"gotistobart","kind":"drug","name":"Gotistobart","route":"/drugs/gotistobart/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"oncoc4","kind":"company","name":"OncoC4","route":"/companies/oncoc4/"}]}}